Gri bio completes enrollment in phase 2a study of gri-0621 for the treatment of idiopathic pulmonary fibrosis (“ipf”)

Currently available treatments for ipf are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival

GRI Ratings Summary

GRI Quant Ranking